Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Boceprevir and personalized medicine in hepatitis C virus infection.

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF.

Pharmgenomics Pers Med. 2012;5:125-37. doi: 10.2147/PGPM.S24259. Epub 2012 Sep 26.

2.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
3.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
4.

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.

Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F.

J Viral Hepat. 2014;21(9):e98-e107. doi: 10.1111/jvh.12237. Epub 2014 Feb 25.

PMID:
24612466
5.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
6.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
7.

Current progress in the treatment of chronic hepatitis C.

Alexopoulou A, Papatheodoridis GV.

World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060. Review.

8.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
9.

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Review.

PMID:
21828346
10.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
11.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
12.

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J.

Clin Ther. 2015 Jul 1;37(7):1529-40. doi: 10.1016/j.clinthera.2015.05.003. Epub 2015 May 29.

PMID:
26031617
13.

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F.

J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4. Review.

PMID:
24012819
14.

Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.

Kwo PY.

Therap Adv Gastroenterol. 2012 May;5(3):179-88. doi: 10.1177/1756283X11436317.

15.

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 17;(6):CD011132. doi: 10.1002/14651858.CD011132.pub2. Review.

PMID:
24937404
16.

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.

Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.

World J Gastroenterol. 2014 Nov 28;20(44):16726-33. doi: 10.3748/wjg.v20.i44.16726.

17.

[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].

Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I.

Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893. Hungarian.

PMID:
24631886
18.

Is response-guided therapy being applied in the clinical setting? The hepatitis C example.

Harris JB, Ward MA, Schwab P.

Am Health Drug Benefits. 2015 Feb;8(1):22-8.

19.

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.

Welch NM, Jensen DM.

Liver Int. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715. Review.

PMID:
25529082
20.

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Review. German.

PMID:
22222799

Supplemental Content

Support Center